Co-Authors
This is a "connection" page, showing publications co-authored by ANTHONY LUCCI and GAIANE MARGISHVILI RAUCH.
Connection Strength
0.613
-
Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA. BMC Cancer. 2024 Aug 16; 24(1):1016.
Score: 0.245
-
Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy: A Nonrandomized Clinical Trial. JAMA Netw Open. 2023 09 05; 6(9):e2333933.
Score: 0.057
-
Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint. J Am Coll Surg. 2023 07 01; 237(1):101-108.
Score: 0.055
-
Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2022 12; 23(12):1517-1524.
Score: 0.054
-
Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2019 Oct; 26(10):3071-3079.
Score: 0.043
-
Ductal Carcinoma In Situ and Margins <2?mm: Contemporary Outcomes With Breast Conservation. Ann Surg. 2019 01; 269(1):150-157.
Score: 0.041
-
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951.
Score: 0.040
-
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer. Br J Surg. 2018 04; 105(5):535-543.
Score: 0.039
-
Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017 07 01; 152(7):665-670.
Score: 0.037